Potential mechanisms involved on how systemic IgG antibodies specific to vascular endothelial growth factor (VEGF) and induced by active immunotherapy decrease platelet derived free-VEGF

References

• Banerjee M, Whiteheart SW. The ins and outs of endocytic trafficking in platelet functions. Curr Opin Hematol 2017;24:467–474. Epub 2017/06/27.
   PubMed Web of Science ®Google Scholar
• Mellman I, Yarden Y. Endocytosis and cancer. Cold Spring Harb Perspect Biol 2013;5:a016949. Epub 2013/12/04.
   PubMed Web of Science ®Google Scholar
• Lowenstein CJ. VAMP-3 mediates platelet endocytosis. Blood 2017;130:2816–2818. Epub 2017/12/30.
   PubMed Web of Science ®Google Scholar
• Banerjee M. PLATELET ENDOCYTOSIS: ROLES IN HEMOSTASIS AND INNATE IMMUNITY. Theses and Dissertations–Molecular and Cellular Biochemistry 2017.
   Google Scholar
• Wojtukiewicz MZ, Sierko E, Hempel D, Tucker SC, Honn KV. Platelets and cancer angiogenesis nexus. Cancer Metastasis Rev 2017;36:249–262.
   PubMed Web of Science ®Google Scholar
• Kut C, Mac Gabhann F, Popel AS. Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br J Cancer 2007;97:978–985. Epub 2007/10/04.
   PubMed Web of Science ®Google Scholar
• Sobolewska B, Fehrenbacher B, Münzer P, Kalbacher H, Geue S, Stellos K, Schaller M, Ziemssen F. Human platelets take up Anti-VEGF agents. J Ophthalmol 2021;2021:8811672.
   PubMed Web of Science ®Google Scholar
• Verheul HM, Hoekman K, Luykx-de Bakker S, Eekman CA, Folman CC, Broxterman HJ, Pinedo HM. Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 1997;3:2187–2190. Epub 1998/11/17.
   PubMed Web of Science ®Google Scholar
• Seria E, Samut Tagliaferro S, Cutajar D, Galdies R, Felice A. Immunoglobulin G in platelet-derived wound healing factors. Biomed Res Int 2021;2021:4762657. Epub 2021/02/13.
   PubMed Web of Science ®Google Scholar
• Verheul HM, Lolkema MP, Qian DZ, Hilkes YH, Liapi E, Akkerman JW, Pili R, Voest EE. Platelets take up the monoclonal antibody bevacizumab. Clin Cancer Res 2007;13:5341–5347. Epub 2007/09/15.
   PubMed Web of Science ®Google Scholar
• Huang ZY, Chien P, Indik ZK, Schreiber AD. Human platelet FcγRIIA and phagocytes in immune-complex clearance. Mol Immunol 2011;48:691–696. Epub 2010/12/21.
   PubMed Web of Science ®Google Scholar
• Qiao J, Al-Tamimi M, Baker RI, Andrews RK, Gardiner EE. The platelet Fc receptor, FcγRIIa. Immunol Rev 2015;268:241–252. Epub 2015/10/27.
   PubMed Web of Science ®Google Scholar
• Arman M, Krauel K. Human platelet IgG Fc receptor FcγRIIA in immunity and thrombosis. J Thrombosis Haemostasis 2015;13:893–908. Epub 2015/04/23.
   PubMed Web of Science ®Google Scholar
• Xu H, Zou X, Xia P, Aboudi MAK, Chen R, Huang H. Differential effects of platelets selectively activated by protease-activated receptors on meniscal cells. Am J Sports Med 2020;48:197–209. Epub 2019/11/26.
   PubMed Web of Science ®Google Scholar
• Sabrkhany S, Griffioen AW, Oude Egbrink MG. The role of blood platelets in tumor angiogenesis. Biochim Biophys Acta 2011;1815:189–196. Epub 2010/12/21.
   PubMed Web of Science ®Google Scholar
• Qi C, Wei B, Zhou W, Yang Y, Li B, Guo S, Li J, Ye J, Li J, Zhang Q, et al. P-selectin-mediated platelet adhesion promotes tumor growth. Oncotarget 2015;6:6584–6596. Epub 2015/03/13.
   PubMed Web of Science ®Google Scholar
• George ML, Eccles SA, Tutton MG, Abulafi AM, Swift RI. Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging? Clin Cancer Res 2000;6:3147–3152. Epub 2000/08/24.
   PubMed Web of Science ®Google Scholar
• Han H, Cao FL, Wang BZ, Mu XR, Li GY, Wang XW. Expression of angiogenesis regulatory proteins and epithelial-mesenchymal transition factors in platelets of the breast cancer patients. TheScientificWorldJournal 2014;2014:878209. Epub 2014/11/08.
   PubMedGoogle Scholar
• Peterson JE, Zurakowski D, Italiano JE Jr., Michel LV, Connors S, Oenick M, D’Amato RJ, Klement GL, Folkman J. VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients. Angiogenesis 2012;15:265–273. Epub 2012/03/10.
   PubMed Web of Science ®Google Scholar
• Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer 2013;13:871–882.
   PubMed Web of Science ®Google Scholar
• Ntellas P, Mavroeidis L, Gkoura S, Gazouli I, Amylidi A-L, Papadaki A, Zarkavelis G, Mauri D, Karpathiou G, Kolettas E. Old player-new tricks: non angiogenic effects of the VEGF/VEGFR pathway in cancer. 2020;12:3145.
   Google Scholar
• Liu C, Workman CJ, Vignali DA. Targeting regulatory T cells in tumors. FEBS J 2016;283:2731–2748. Epub 2016/01/21.
   PubMed Web of Science ®Google Scholar
• Albini A, Bruno A, Noonan DM, Mortara L. Contribution to tumor angiogenesis from innate immune cells within the tumor microenvironment: implications for immunotherapy. Front Immunol 2018;9:527. Epub 2018/04/21.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Nomura Y, Nishida J, Fujino Y, Yanagi Y, Kawashima H. Vascular endothelial growth factor (VEGF) concentration is underestimated by enzyme-linked immunosorbent assay in the presence of Anti-VEGF drugs. Invest Ophthalmol Vis Sci 2016;57:462–466. Epub 2016/02/13.
   PubMed Web of Science ®Google Scholar
• Rahimi N. VEGFR-1 and VEGFR-2: two non-identical twins with a unique physiognomy. Front Biosci 2006;11:818–829.
   PubMed Web of Science ®Google Scholar
• Y-l L, Zhao H, Ren X-B. Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward? Cancer Biol Med 2016;13:206–214.
   PubMed Web of Science ®Google Scholar
• Lapeyre-Prost A, Terme M, Pernot S, Pointet AL, Voron T, Tartour E, Taieb J. Immunomodulatory Activity of VEGF in Cancer. Int Rev Cell Mol Biol 2017;330:295–342. Epub 2017/02/22.
   PubMed Web of Science ®Google Scholar
• Wentink MQ, Huijbers EJ, de Gruijl TD, Verheul HM, Olsson AK, Griffioen AW. Vaccination approach to anti-angiogenic treatment of cancer. Biochim Biophys Acta 2015;1855:155–171. Epub 2015/02/03.
   PubMed Web of Science ®Google Scholar
• Kong D-H, Kim MR, Jang JH, H-j N, Lee S. A review of anti-angiogenic targets for monoclonal antibody cancer therapy. Int J Mol Sci 2017;18:1786.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buque A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, et al. Classification of current anticancer immunotherapies. Oncotarget 2014;5:12472–12508. Epub 2014/12/30.
   PubMed Web of Science ®Google Scholar
• Morera-Díaz Y, Gavilondo JV, Bequet-Romero M, Sánchez Ramírez J, Hernández-Bernal F, Selman-Housein K-H, Perez L, Ayala-Ávila M. Specific active immunotherapy with the HEBERSaVax VEGF-based cancer vaccine: from bench to bedside. Semin Oncol 2018;45:68–74.
   PubMed Web of Science ®Google Scholar
• Gavilondo JV, Hernández F, Ayala M, de la Torre AV, de la Torre J, Morera Y, Bequet M, Sánchez J, Valenzuela CM, Martin Y, et al. Specific active immunotherapy with a VEGF vaccine in patients with advanced solid tumors. results of the CENTAURO antigen dose escalation phase I clinical trial. Vaccine 2014;32:2241–2250. Epub 2014/02/18.
   PubMed Web of Science ®Google Scholar
• Goedegebuure RSA, Wentink MQ, van der Vliet HJ, Timmerman P, Griffioen AW, de Gruijl TD, and Verheul HMW. A phase I open-label clinical trial evaluating the therapeutic vaccine hVEGF26-104/RFASE in patients with advanced solid malignancies. Oncologist 202026:e218-e229o9. Epub 2020/10/27.
   PubMed Web of Science ®Google Scholar
• Sánchez Ramírez J, Morera Díaz Y, Bequet-Romero M, Hernández-Bernal F, Selman-Housein Bernal K-H, de la Torre Santos A, Santiesteban Álvarez ER, Martín Bauta Y, Bermúdez Badell CH, de la Torre Pupo J, et al. Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants. BMC Immunol 2017;18:39.
   PubMed Web of Science ®Google Scholar
• Morera Y, Bequet M, Ayala M, Lamdán H, Agger EM, Andersen P, Gavilondo JV. Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants. Angiogenesis 2008;11:381–393. Epub 2008/11/27.
   PubMed Web of Science ®Google Scholar
• Sánchez Ramírez J, Morera Diaz Y, Bequet-Romero M, Hernandez-Bernal F, Martin Bauta Y, Selman-Housein Bernal KH, de la Torre Santos AV, Perez de la Iglesia M, Trimino Lorenzo L, Ayala Avila M. Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program. BMC Immunol 2020;21:12. Epub 2020/03/17.
   PubMed Web of Science ®Google Scholar
• Adams J, Carder PJ, Downey S, Forbes MA, MacLennan K, Allgar V, Kaufman S, Hallam S, Bicknell R, Walker JJ, et al. Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res 2000;60:2898–2905. Epub 2000/06/13.
   PubMed Web of Science ®Google Scholar
• Sánchez Ramírez J, Bequet-Romero M, Morera Díaz Y, Hernández-Bernal F, Ayala Avila M. Does VEGF-targeted active immunotherapy induce complete abrogation of platelet VEGF levels? BMC Res Notes 2019;12:323.
   PubMed Web of Science ®Google Scholar
• Morera Y, Sánchez J, Bequet-Romero M, Selman-Housein KH, de la Torre A, Hernández-Bernal F, Martin Y, Garabito A, Pinero J, Bermúdez C, et al. Specific humoral and cellular immune responses in cancer patients undergoing chronic immunization with a VEGF-based therapeutic vaccine. Vaccine 2017;35:3582–3590. Epub 2017/05/26.
   PubMed Web of Science ®Google Scholar